Vernalis PLC Block listing Interim Review (2594A)
29 March 2017 - 7:00PM
UK Regulatory
TIDMVER
RNS Number : 2594A
Vernalis PLC
29 March 2017
BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING
APPLICATION
VERNALIS PLC (the "Company")
29 March 2017
Vernalis plc (LSE: VER) provides the following update in
accordance with Schedule Six of the AIM Rules for Companies
regarding its existing block listing arrangements:
Name of applicant: Vernalis plc
---------------------------- -------------------------------------------------
Name of scheme(s): 2007 Long Term Incentive
Scheme ("LTIP") and 2016
Executive Incentive Plan
("EIP")
---------------------------- -------------------------------------------------
Period of return From: 29/Sept/2016 To: 29/March/2017
(from / to):
---------------------------- ------------------------- ----------------------
Balance of unallotted Total of 401,056 Ordinary
securities under 1p Shares under LTIP
scheme(s) from previous
return:
---------------------------- -------------------------------------------------
Plus: The amount Total of 499,612 Ordinary
by which the block 1p Shares, split:
scheme(s) has been * Under LTIP = 199,026 Ordinary 1p Shares
increased or application
has been made to
increase since the * Under EIP = 300,586 Ordinary 1p Shares
date of the last
return (if any increase
has been applied As applied for in the
for): below paragraph.
---------------------------- -------------------------------------------------
Less: Number of securities Total of 163,876 Ordinary
issued/allotted under 1p Shares under LTIP
scheme(s) during
period:
---------------------------- -------------------------------------------------
Less: Number of securities Total of 8,001 Ordinary
forfeited under scheme(s) 1p Shares under LTIP
during period:
---------------------------- -------------------------------------------------
Equals: Balance under Total of 728,791 Ordinary
scheme(s) not yet 1p Shares, split:
issued/allotted at * Under LTIP = 428,205 Ordinary 1p Shares
end of period:
* Under EIP = 300,586 Ordinary 1p Shares
---------------------------- -------------------------------------------------
Number and class No. of Date on which
of securities originally Ordinary Shares were Admitted
admitted and the 1p Shares to Trading
date of admission ----------- ----------------------
(including any additions): 350,000 6 November 2013,
plus
----------- ----------------------
1,049,317 12 May 2014,
plus
----------- ----------------------
1,058,184 12 May 2015,
plus
----------- ----------------------
1,638,364 30 September
2015
----------- ----------------------
1,189,296 1 April 2016
----------- ----------------------
499,612 31 March 2017
----------- ----------------------
---------------------------- -------------------------------------------------
BLOCK LISTING APPLICATION
Vernalis plc announces that application has been made to the
London Stock Exchange for the admission of 499,612 Ordinary Shares
of 1 pence each (the "Ordinary Shares") in the Company under the
Company's existing block listing scheme. These Ordinary Shares will
be available to satisfy future exercises of options over Ordinary
Shares under the Company's employee share schemes being: the LTIP;
and the EIP. It is expected that admission will become effective on
31 March 2017. When issued, these shares will rank pari passu with
the existing Ordinary Shares.
-- ends -
Enquiries:
+44 (0) 118 938
Vernalis plc: 0015
Ian Garland, Chief Executive
Officer
David Mackney, Chief Financial
Officer
Canaccord Genuity Limited
(Nominated Adviser and Joint +44 (0) 20 7523
Broker): 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
+44 (0) 20 7408
Shore Capital (Joint Broker): 4090
Bidhi Bhoma
Toby Gibbs
+44 (0) 20 3727
FTI Consulting: 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR
targeting the US prescription cough-cold market; Moxatag(R) , a
once-daily formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focused on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last five years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit
www.vernalis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRJTMLTMBATBFR
(END) Dow Jones Newswires
March 29, 2017 04:00 ET (08:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024